Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) on Behalf of Investors

Fulcrum Therapeutics discontinued its pociredir sickle cell disease program after the FDA concluded that PRC2-targeting interventions carry an equivalent malignancy risk, leaving no viable regulatory path for further development. The announcement drove FULC shares down 51.09%, from $6.42 on June 1 to $3.14 on June 2, 2026. Kaplan Fox & Kilsheimer is investigating potential securities-law violations related to the program's termination.

Analysis

The relevant incremental signal is not the law-firm solicitation—these announcements rarely create standalone fundamental downside—but the apparent class-wide regulatory read-through on PRC2 targeting. FULC’s equity value is now principally a cash-runway and remaining-pipeline underwriting exercise; without a credible replacement indication or partnership, the market is likely to apply a steep discount to cash because fixed public-company costs and development spend consume optionality. The key diligence item is pro forma cash net of wind-down commitments and the timing of management’s next capital-allocation decision.

Over the next 1-3 months, expect residual selling from biotech holders whose mandate requires active clinical catalysts, plus heightened scrutiny of prior disclosures around regulatory interactions. Litigation can add D&O and management-distraction costs, but it is unlikely to be material relative to the lost program value unless discovery uncovers evidence that the regulatory risk was known materially earlier. BAC and ALV have no actionable read-through from this item despite their inclusion in the ticker data.

The contrarian case is that the post-event drawdown may have converted FULC into a cash-backed special situation: if enterprise value falls materially below conservatively estimated net cash, a board-led restructuring, asset sale, or reverse-merger option can create asymmetric upside over 6-18 months. That is not yet a long thesis without verified quarterly cash, remaining program economics, and evidence that the company will curtail burn; clinical-stage biotech cash discounts can persist when governance and capital-allocation credibility are weak.

Key Decisions for Investors

• No new directional short solely on the litigation notice; treat it as an alert, not a catalyst. Reassess after the next 10-Q for net cash, quarterly operating burn, severance/wind-down charges, and any revision to remaining-pipeline guidance.
• Establish a cash-value watch: consider a small, event-driven FULC long only if fully diluted enterprise value is at least 30-40% below verified net cash after estimated 12-month burn and liabilities. Target 6-12 months; exit if management preserves historical burn or raises capital below cash value.
• For existing FULC longs, reduce exposure ahead of the next earnings/corporate-update window unless management provides a quantified runway extension, asset monetization plan, or externally validated remaining-program catalyst. The principal downside is continued burn toward a sub-cash valuation rather than incremental lawsuit headlines.
• Monitor PRC2-exposed private/public biotech peers and licensing counterparties for explicit FDA communications before extrapolating a sector short. A regulator view limited to this molecular context would sharply weaken any broad target-class thesis.